尖端计算机软件可精确找到恶性乳腺癌肿瘤

Researchers at Western University are using cutting-edge genetic¹ mutation²-analysis software developed in their lab to interpret mutations in tumour³ genome that may provide insight into determining which breast cancer tumours⁴ are more likely spread to other parts of the body and which ones won't. Their findings are published today in the journal, Nature Scientific Reports.   "We are using a unique software program in our lab that looks at a type of mutation called a splicing⁵ mutation that is typically overlooked using current methods," said lead author on the study, Stephanie Dorman, a PhD student in the department of biochemistry at Western University's Schulich School of Medicine & Dentistry. She said that where previous genetic studies of 445 tumours detected 429 of these splicing mutations, the Western-developed analysis software was able to find more than 5000.   Using this software and human tumour tissue sample genetic data from The Cancer Genome Atlas⁶, the research team pinpointed⁷ that mutations in the Neural⁸ Cell Adhesion Molecule⁹ (NCAM) and other related genes¹⁰ in NCAM biology were present at a much higher rate in tumours which had metastasized to the lymph nodes than those that did not. NCAM, typically found in neural cells is also highly expressed in breast tissue, and is involved in communication between cells.   "We believe that mutations in these biological pathways in some patients might be causing some of the characteristics of the tumour that enable it to migrate to other parts of the body," said Dorman.   Dr. Peter Rogan, principal investigator¹¹ on the study and a Professor in the Departments of Biochemistry and Computer Science, hopes that these findings will allow oncologists and clinical laboratories looking for these mutations in tumour biopsies to predict which women are at higher risk for more aggressive tumours that might metastasize.   "One of the big issues in breast oncology is that women are sometimes treated with chemotherapy even if their tumour isn't going to metastasize," said Rogan. "The ideal situation would be to be able to identify those patients where the side-effects and potential negative consequences of chemotherapy following surgery can be avoided or at least, minimized."